Research has demonstrated that omega-3 EFAs are beneficial for cardiovascular health and are linked to benefits associated with fertility, joint mobility, brain health, fetal development, improved behavior/mood, and anti-aging. Unfortunately, it is well-known in the medical community that EFAs are poorly absorbed in the body after consumed, which leads to larger capsules and higher serving counts to achieve optimal therapeutic blood levels. In addition, EFAs are also known to be heavily food dependent for optimal oral absorption and bioavailability.
To overcome these obstacles, SourceOne leverages the VESIsorb® delivery system, therefore achieving industry benchmarks for unprecedented active loading, improved bioavailability, and mitigating food dependency. Human clinical trials have demonstrated the dramatic improvement in pharmacokinetic performance (Cmax, Tmax, and AUC) of omega-3 EFA VESIsorb® formulations, showing up to a 26-fold improvement compared to a leading Rx brand.
The benefits are unmatched:
- Faster onset, independent of food/fat status.
- Fewer servings required to achieved the desired therapeutic effect.
- Superior loading for smaller and easier to consumer capsules.
- Addressing issues related to poor absorption like age, diet, and gender.
Simply put, this formula delivers unmatched blood plasma levels of both EPA and DHA in one softgel capsule.
While consumer compliance is a major concern for medical professionals recommending omega-3 solution, fewer servings are required of OMEGACHOICE® (compared to other omega-3 solutions) to achieve the desired therapeutic effect which dramatically improves this concern.
